<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110939">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01890265</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-3019-067</org_study_id>
    <nct_id>NCT01890265</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of FG-3019 in subjects with IPF, and the efficacy of
      FG-3019 in slowing the loss of forced vital capacity (FVC) and the progression of IPF in
      these subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in FVC (percent of predicted value) at Week 48.</measure>
    <time_frame>Day 1 to Week 48</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in health-related quality of life at Week 48.</measure>
    <time_frame>Day 1 to Week 48</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subject-reported dyspnea at Week 48.</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression of IPF, defined as time from Day 1 to any one of the following</measure>
    <time_frame>Day 1 to anyone of the following below:</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>First respiratory-related hospitalization.
Respiratory-related death.
Absolute decline in FVC percent of predicted value of ≥10%.
Absolute decline in DLCO, adjusted for Hgb, percent of predicted value of ≥15%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least one respiratory-related hospitalization</measure>
    <time_frame>Week 52</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with respiratory-related death, censored at Week 52.</measure>
    <time_frame>Week 52</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical assessment of absolute change from baseline in FVC percent of predicted value at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 48 in computer-assisted scores of percent of area of lung parenchymal fibrosis</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Study Drug (FG-3019)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Drug, FG-3019, 30 mg/kg; 10 mg/ml, single dose vials, by intravenous infusion every 3 weeks for a total of 16 infusions over 45 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile, clear aqueous solution, 10 mg/ml, single dose vials, by intravenous infusion every 3 weeks for a total of 16 infusions over 45 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-3019</intervention_name>
    <description>Study Drug, FG-3019, 10 mg/ml, single dose vials, by intravenous infusion every 3 weeks for a total of 16 infusions over 45 weeks</description>
    <arm_group_label>Study Drug (FG-3019)</arm_group_label>
    <other_name>Fully human recombinant IgG, kappa monoclonal anti-body.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile, clear aqueous solution, 10 mg/ml, single dose vials, by intravenous infusion every 3 weeks for a total of 16 infusions over 45 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 40 to 80 years, inclusive.

          2. Clinical diagnosis of IPF by high resolution computed tomography (HRCT) scan (and in
             some cases by surgical lung biopsy) and reduced lung function (forced vital
             capacity).

          3. History of IPF of 4 years' duration or less.

          4. Forced Vital Capacity (FVC)  55% to 90% of predicted value at screening.

          5. Women of childbearing potential, and men, must be willing to use a medically
             acceptable method of contraception during the trial and 3 months after the last dose
             of study drug.

          6. All subjects whose FVC percent predicted value (mean of Week 36 and Week 48 values)
             shows less than 3% absolute decrease from baseline (mean of Screening Visit 1 and Day
             1 values) in the Randomized Treatment Phase will be offered participation in an
             Extended Treatment Phase.

        Exclusion Criteria:

          1. Women who are pregnant or nursing.

          2. History of any other types of lung or heart disease and any other medical conditions
             that, in the opinion of the investigator, would preclude the subject's participation
             in the study.

          3. Clinically important abnormal laboratory tests.

          4. Upper or lower respiratory tract infection of any type within 4 weeks of the first
             screening visit.

          5. Acute exacerbation of IPF within 3 months of the first screening visit.

          6. Use of certain medications and investigational drugs within 4 weeks of the first
             screening visit.

          7. History of cancer of any type in the 5 years preceding the first screening visit,
             excluding non-melanomatous skin cancer, localized bladder cancer, or in situ cervical
             cancer.

          8. Diffusing capacity (DLCO) less than 30% of predicted value at screening.

          9. History of allergic or anaphylactic reaction to human, humanized, chimeric or murine
             monoclonal antibodies.

         10. Previous treatment with FG-3019.

         11. Body weight greater than 130 kilograms.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Wencel, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Via Christi Clinic, P.A.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joao de Andrade, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Kirklin Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Riley, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers, The State University of New Jersey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter LaCamera, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steward St. Elizabeth's Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Danielle Antin-Ozerkis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Allen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rishi Raj, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neil Ettinger, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Luke's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Perez, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Chan, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin DeBoer, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Florida Pulmonary Group, PA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yolanda Mageto, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vermont Lung Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Srihari Veeraraghavan, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Markus Gutsche, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cinncinati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Gibson, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisa Lancaster, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Scholand, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah - Lung Health Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Ruzi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arizona Pulmonary Specialists, LTD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Rolfe, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampa General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Hamblin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Culver, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John L. Stauffer, M.D</last_name>
    <phone>415-978-1455</phone>
    <email>jstauffer@fibrogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Loredie Lugis, RN-BSN</last_name>
    <phone>415-978-1353</phone>
    <email>llugos@fibrogen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Kirklin Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joao de Andrade, M.D.</last_name>
      <phone>205-934-6229</phone>
      <email>joao@uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Angela Lewis</last_name>
      <phone>(205) 934-6229</phone>
      <email>adlewis@uab.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joao de Andrade, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialists, LTD</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Ruzi, M.D.</last_name>
      <phone>480-657-7254</phone>
      <email>docjon@cox.net</email>
    </contact>
    <contact_backup>
      <last_name>Marlys Walrath, CCRC</last_name>
      <phone>480 657 7254</phone>
      <email>marlys-research@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan Ruzi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oanh Nguyen</last_name>
      <phone>916-734-3755</phone>
      <email>oanh.nguyen@ucdmc.ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Carolyn King</last_name>
      <phone>916-734-3560</phone>
      <email>carolyn.king@ucdmc.ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Chan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Antin-Ozerkis, M.D.</last_name>
      <phone>203-785-7324</phone>
      <email>danielle.antin-ozerkis@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jean Estrom</last_name>
      <phone>203-785-7324</phone>
      <email>jean.estrom@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Danielle Antin-Ozerkis, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Florida Pulmonary Group, PA</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise P Smith</last_name>
      <phone>407-841-1100</phone>
      <phone_ext>107</phone_ext>
      <email>dpsmith@cfpulmonary.com</email>
    </contact>
    <contact_backup>
      <last_name>Shari Tillman, RN, BSN, CCRC</last_name>
      <phone>407-841-1100</phone>
      <phone_ext>122</phone_ext>
      <email>stillman@cfpulmonary.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin DeBoer, D.O.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampl</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Rolfe, M.D</last_name>
      <phone>813-844-3430</phone>
      <email>lungtxp@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Fowler, M.D.</last_name>
      <phone>813-844-3430</phone>
      <email>bfarlow@tgh.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Rolfe, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Halaby, RN</last_name>
      <phone>404-712-7458</phone>
      <email>tracy.halaby@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jane Gillespie, RN</last_name>
      <phone>404-712-8204</phone>
      <email>jegille@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Srihari Veeraraghavan, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rishi Raj, M.D.</last_name>
      <phone>312-695-2269</phone>
      <email>rishi.raj@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Margaret Travis, Rn, BSN</last_name>
      <phone>312-695-2269</phone>
      <email>margaret.travis@northwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rishi Raj, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Hamblin, M.D.</last_name>
      <phone>913-588-6045</phone>
      <email>mhamblin@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marla Watson, M.D.</last_name>
      <phone>913-588-4022</phone>
      <email>mwatson5@kumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Hamblin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Via Christi Clinic, P.A.</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Wencel, MD</last_name>
      <phone>316-689-9542</phone>
      <email>mark.wencel@viachristi.org</email>
    </contact>
    <contact_backup>
      <last_name>Angel Vincent</last_name>
      <phone>316-689-9542</phone>
      <email>angela.vincent@viachristi.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Wencel, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamra Perez</last_name>
      <phone>502-852-1358</phone>
      <email>tamra.perez@louisville.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heidi Wilson</last_name>
      <phone>502-852-0560</phone>
      <email>Heidi.wilson@louisville.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rafael Perez, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Steward St. Elizabeth's Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter LaCamera, M.D.</last_name>
      <phone>617-789-2078</phone>
      <email>peter.lacamera@steward.org</email>
    </contact>
    <contact_backup>
      <last_name>Arthur Dea</last_name>
      <phone>617-789-2078</phone>
      <email>arthur.dea@steward.org</email>
    </contact_backup>
    <investigator>
      <last_name>Peter LaCamera, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Shipp, RRT, CCRC</last_name>
      <phone>314-576-4501</phone>
      <email>anna.shipp@stlukes-stl.com</email>
    </contact>
    <contact_backup>
      <last_name>Sue Meril, RRT, CCRC</last_name>
      <phone>314-576-4501</phone>
      <email>sue.merli@stlukes-stl.com</email>
    </contact_backup>
    <investigator>
      <last_name>Neil Ettinger, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson Medical School</name>
      <address>
        <city>Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Riley, M.D.</last_name>
      <phone>732-418-8483</phone>
      <email>riley@umdnj.edu</email>
    </contact>
    <contact_backup>
      <last_name>Halina Malveaux</last_name>
      <phone>732-418-8483</phone>
      <email>malveaha@umdnj.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David Riley, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cinncinati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Ingledue, CCRC</last_name>
      <phone>513-558-0027</phone>
      <email>Rebecca.Ingledue@uc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tammy Roads, CCRC</last_name>
      <phone>513-558-2148</phone>
      <email>roadst@uc.mail.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Markus Gutsche, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Culver, D.O.</last_name>
      <phone>216-444-6508</phone>
      <email>culverd@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Ron Wehrmann, BA, RRT</last_name>
      <phone>216-445-0574</phone>
      <email>wehrmar@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Culver, D.O</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Allen, M.D.</last_name>
      <phone>614-366-2361</phone>
      <email>James.Allen@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rachael Compton</last_name>
      <phone>614-366-2361</phone>
      <email>Rachael.compton@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James Allen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Meyers, BSN, RN</last_name>
      <phone>412-692-2149</phone>
      <email>meyersma@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michelle MacPherson</last_name>
      <phone>412-647-4537</phone>
      <email>macphersonmj@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin Gibson, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-5735</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Lancaster, M.D.</last_name>
      <phone>615-343-7068</phone>
      <email>lisa.lancaster@vanderbilt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen Kinser, BSN, RN</last_name>
      <phone>615-343-7068</phone>
      <email>kathleen.j.kinser@vanderbilt.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lisa Lancaster, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah - Lung Health Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Scholand, M.D.</last_name>
      <phone>801-581-5864</phone>
      <email>scholand@genetics.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Spencer Whipple, BS, CRC</last_name>
      <phone>801-581-5864</phone>
      <email>spencer.whipple@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mary Scholand, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vermont Lung Center</name>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <zip>05446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Lutton, B.A., CCRP</last_name>
      <phone>802-847-2160</phone>
      <email>patricia.lutton@vtmednet.org</email>
    </contact>
    <contact_backup>
      <last_name>Joan Lippmann, B.S.</last_name>
      <phone>802-847-6982</phone>
      <email>joan.lippmann@vtmednet.org</email>
    </contact_backup>
    <investigator>
      <last_name>Yolanda Mageto, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>June 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic Pulmonary Fibrosis, IPF, Idiopathic Interstitial Pneumonia, Interstitial Lung Disease, Lung Fibrosis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
